Cargando…
Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model
3,5-Diiodothyronine (3,5-T2) has been shown to exert pleiotropic beneficial effects. In this study we investigated whether 3,5-T2 prevent several energy metabolism disorders related to type 2 diabetes mellitus (T2DM) in gerbils diabetes-prone P. obesus. 157 male gerbils were randomly to Natural Diet...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329750/ https://www.ncbi.nlm.nih.gov/pubmed/35893898 http://dx.doi.org/10.3390/nu14153044 |
_version_ | 1784757990635601920 |
---|---|
author | Bouazza, Asma Favier, Roland Fontaine, Eric Leverve, Xavier Koceir, Elhadj-Ahmed |
author_facet | Bouazza, Asma Favier, Roland Fontaine, Eric Leverve, Xavier Koceir, Elhadj-Ahmed |
author_sort | Bouazza, Asma |
collection | PubMed |
description | 3,5-Diiodothyronine (3,5-T2) has been shown to exert pleiotropic beneficial effects. In this study we investigated whether 3,5-T2 prevent several energy metabolism disorders related to type 2 diabetes mellitus (T2DM) in gerbils diabetes-prone P. obesus. 157 male gerbils were randomly to Natural Diet (ND-controlled) or a HED (High-Energy Diet) divided in: HED- controlled, HED-3,5-T2 and HED- Placebo groups. 3,5-T2 has been tested at 25 µg dose and was administered under subcutaneous pellet implant during 10 weeks. Isolated hepatocytes were shortly incubated with 3,5-T2 at 10(−6) M and 10(−9) M dose in the presence energetic substrates. 3,5-T2 treatment reduce visceral adipose tissue, prevent the insulin resistance, attenuated hyperglycemia, dyslipidemia, and reversed liver steatosis in diabetes P. obesus. 3,5-T2 decreased gluconeogenesis, increased ketogenesis and enhanced respiration capacity. 3,5-T2 potentiates redox and phosphate potential both in cytosol and mitochondrial compartment. The use of 3,5-T2 as a natural therapeutic means to regulate cellular energy metabolism. We suggest that 3,5-T2 may help improve the deleterious course of obesity and T2DM, but cannot replace medical treatment. |
format | Online Article Text |
id | pubmed-9329750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93297502022-07-29 Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model Bouazza, Asma Favier, Roland Fontaine, Eric Leverve, Xavier Koceir, Elhadj-Ahmed Nutrients Article 3,5-Diiodothyronine (3,5-T2) has been shown to exert pleiotropic beneficial effects. In this study we investigated whether 3,5-T2 prevent several energy metabolism disorders related to type 2 diabetes mellitus (T2DM) in gerbils diabetes-prone P. obesus. 157 male gerbils were randomly to Natural Diet (ND-controlled) or a HED (High-Energy Diet) divided in: HED- controlled, HED-3,5-T2 and HED- Placebo groups. 3,5-T2 has been tested at 25 µg dose and was administered under subcutaneous pellet implant during 10 weeks. Isolated hepatocytes were shortly incubated with 3,5-T2 at 10(−6) M and 10(−9) M dose in the presence energetic substrates. 3,5-T2 treatment reduce visceral adipose tissue, prevent the insulin resistance, attenuated hyperglycemia, dyslipidemia, and reversed liver steatosis in diabetes P. obesus. 3,5-T2 decreased gluconeogenesis, increased ketogenesis and enhanced respiration capacity. 3,5-T2 potentiates redox and phosphate potential both in cytosol and mitochondrial compartment. The use of 3,5-T2 as a natural therapeutic means to regulate cellular energy metabolism. We suggest that 3,5-T2 may help improve the deleterious course of obesity and T2DM, but cannot replace medical treatment. MDPI 2022-07-25 /pmc/articles/PMC9329750/ /pubmed/35893898 http://dx.doi.org/10.3390/nu14153044 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bouazza, Asma Favier, Roland Fontaine, Eric Leverve, Xavier Koceir, Elhadj-Ahmed Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model |
title | Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model |
title_full | Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model |
title_fullStr | Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model |
title_full_unstemmed | Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model |
title_short | Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model |
title_sort | potential applications of thyroid hormone derivatives in obesity and type 2 diabetes: focus on 3,5-diiodothyronine (3,5-t2) in psammomys obesus (fat sand rat) model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329750/ https://www.ncbi.nlm.nih.gov/pubmed/35893898 http://dx.doi.org/10.3390/nu14153044 |
work_keys_str_mv | AT bouazzaasma potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel AT favierroland potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel AT fontaineeric potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel AT levervexavier potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel AT koceirelhadjahmed potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel |